CREDIT SUISSE AT1s: Pallas Partners forming Investor Group
Overview
Pallas Partners LLP (“Pallas”) is building a group of holders of Credit Suisse’s Additional Tier 1 Bonds (“AT1s”) wiped out at the weekend as part of the Swiss government-mandated takeover of Credit Suisse by UBS. The group will pursue a multi-faceted litigation strategy to seek to mitigate losses suffered by holders of the AT1s and allow recoveries to be made, through focused litigation against those who have acted to deprive the AT1s of their contractual and other rights.
Pallas is holding an investor call at 4pm UK / 12pm NY on Wednesday 22 March 2023 to discuss the group and the litigation strategy. Please email CSAT1Investors@pallasllp.com for details on how to join the call.
The Investor Group
Since events over the weekend by which the Swiss government and regulators forced through a takeover of Credit Suisse by UBS, a term of which was to write down the AT1s to zero, Pallas has been working with AT1 holders and investors to explore options to recover losses and understand the value play through litigation.
Pallas and investors are focused on the actions of the Swiss authorities (FINMA, the Federal Council and others) to pass through last-minute legislation purportedly providing for this AT1 wipe-out which upended the established claims hierarchy allowing equity holders to remain in the structure to the detriment of the AT1s.
We are exploring a cohesive multi-jurisdictional strategy to be pursued by a cohesive group of international investors in the AT1s, to recover losses.
Investors will be eligible to join the investor group if they held AT1s as at 17 March 2023, or hold AT1s at present. There is no jurisdictional restriction.
The Litigation Strategy
In extraordinary circumstances such as these, it is imperative that investors work together to pursue a litigation strategy designed to litigate against the right defendants in the right jurisdictions. A fractured investor community, spending time litigating in the wrong places against the wrong defendants will not serve the interests of the AT1s, and will not drive recoveries for AT1 holders.
Pallas is therefore building out a litigation strategy which considers both local law remedies and also remedies outside of Switzerland given the international nature of investors and the places in which statements were made to the market regarding CS’ liquidity and solvency position.
Details of the proposed recoveries strategy will be shared on the call, and Pallas can provide more detailed advice once an investor is a member of the group (and subject to confirmation of AT1 holdings).
Investor Call
Pallas’ investor group will take place at 4pm UK / 12pm NY on Wednesday 22 March 2023.
Details of the call are available from CSAT1Investors@pallasllp.com.
About Pallas Partners
Pallas Partners is a London and New York elite litigation firm specialising in high stakes litigation, international arbitration and investigations at the very top end of the market, for the world’s most sophisticated clients. The firm litigates cutting edge and complex cases, including securities litigation in the UK and Europe.
Pallas and its lawyers have an extraordinary depth of experience in litigating matters relating to bank resolutions, bank wind-downs, government interventions and CoCo redemptions and cancellations. We have acted on bank and investor challenges in Iceland, Ireland, UK, Cyprus, Greece, Spain, Portugal, Austria and Ukraine, and have represented holders of CoCo bonds in challenging cancellations and early redemptions, through to the UK Supreme Court.
Pallas is currently representing lenders to Mozambican SPVs in the “tuna bond” litigation against, amongst others, Credit Suisse, before the English Courts. We are also representing Greensill investors with respect to claims against Credit Suisse. Pallas also has an extensive practice acting for special situations and distressed holders in designing and implementing litigation strategies to recover value and create leverage.
Pallas’ Managing Partner Natasha Harrison is leading this mandate. Natasha is one of the leading litigators of the most important investor disputes of the last decade. Natasha is top-ranked in Legal 500 and Chambers & Partners, and is described as a “leading banking litigator” in those publications. Super Lawyers and Lawdragon have named her as a leading commercial litigator and Who’s Who named her as a Restructuring Thought Leader for 2022. In 2021 she won Legal Advisor of the Year at the Women in Finance Awards, she was shortlisted for a Lifetime Achievement Award by the Law Society and for Managing Partner of the Year by Legal Business. She was also listed by Financial News as one of the 50 Most Influential Lawyers in 2022 and as one of the 100 Most Influential Women in European Finance in 2022.
The wider team includes Duane Loft in New York, Fiona Huntriss, Tracey Dovaston and Neil Pigott in London, all of whom have deep experience in these issues.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230321005795/en/
Contact information
Media:
Camarco
Ed Gascoigne-Pees, Partner
Julia Tilley, Partner
+44 (0)7815 068 387
Investors:
Natasha Harrison:
nharrison@pallasllp.com
Pallas AT1 team:
CSAT1@pallasllp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
